Shanghai RAAS Blood Products Co Ltd Class A Cash Flow-to-Debt Ratio
Shanghai RAAS Blood Products Co Ltd Class A cash flow-to-debt ratio. Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow-to-Debt Ratio of -0.16x as of December 2025, meaning its operating cash flow of CN¥-843.75 Million could theoretically repay 0% of its total liabilities (CN¥5.33 Billion) in one year. Check Shanghai RAAS Blood Products Co Ltd Clas cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Cash flow-to-debt ratio of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. Historical debt coverage capacity for Shanghai RAAS Blood Products Co Ltd Class A across 21 annual periods. Check 002252 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow-to-Debt Ratio by Year (2005–2025)
Shanghai RAAS Blood Products Co Ltd Class A cash flow-to-debt ratio by year from 2005 to 2025. Year-by-year debt coverage analysis for Shanghai RAAS Blood Products Co Ltd Class A. For the full cash flow conversion analysis, see Shanghai RAAS Blood Products Co Ltd Clas operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | CN¥-104.89 Million | CN¥5.34 Billion | ▲ +93.1% |
| 2024 | -0.29x | CN¥-482.06 Million | CN¥1.69 Billion | ▼ -128.5% |
| 2023 | 1.00x | CN¥2.28 Billion | CN¥2.28 Billion | ▼ -4.7% |
| 2022 | 1.05x | CN¥1.73 Billion | CN¥1.64 Billion | ▲ +8.0% |
| 2021 | 0.97x | CN¥1.29 Billion | CN¥1.33 Billion | ▼ -69.8% |
| 2020 | 3.21x | CN¥1.17 Billion | CN¥363.74 Million | ▲ +33.3% |
| 2019 | 2.41x | CN¥872.69 Million | CN¥361.95 Million | ▲ +356.1% |
| 2018 | 0.53x | CN¥262.50 Million | CN¥496.56 Million | ▲ +288.5% |
| 2017 | 0.14x | CN¥268.76 Million | CN¥1.98 Billion | ▼ -68.1% |
| 2016 | 0.43x | CN¥638.22 Million | CN¥1.50 Billion | ▼ -52.8% |
| 2015 | 0.90x | CN¥762.42 Million | CN¥843.64 Million | ▲ +46.5% |
| 2014 | 0.62x | CN¥465.96 Million | CN¥755.16 Million | ▲ +424.2% |
| 2013 | -0.19x | CN¥-90.11 Million | CN¥473.37 Million | ▼ -113.6% |
| 2012 | 1.40x | CN¥263.46 Million | CN¥188.79 Million | ▼ -35.5% |
| 2011 | 2.16x | CN¥178.03 Million | CN¥82.26 Million | ▲ +7.1% |
| 2010 | 2.02x | CN¥200.21 Million | CN¥99.12 Million | ▲ +7.8% |
| 2009 | 1.87x | CN¥116.01 Million | CN¥61.88 Million | ▲ +33.1% |
| 2008 | 1.41x | CN¥107.64 Million | CN¥76.42 Million | ▲ +9.4% |
| 2007 | 1.29x | CN¥175.71 Million | CN¥136.53 Million | ▲ +304.4% |
| 2006 | 0.32x | CN¥53.58 Million | CN¥168.39 Million | ▼ -39.9% |
| 2005 | 0.53x | CN¥54.02 Million | CN¥101.93 Million | — |